Targeted Radiopharmaceuticals Manufacturing and Supply Chain Summit

The biggest challenges facing targeted radiopharmaceuticals are the highly complex processes associated with acquiring raw radioisotope APIs, the limited availability of these radionuclides, and getting whole-drug products to patients on time. This can't be done alone! Abdera, Clarity, and Rayze have all recently landed landmark supply deals to fuel their clinical development and there are certainly more to come!

The Targeted Radiopharmaceuticals Manufacturing and Supply Chain Summit is the only industry-led meeting dedicated to plugging the gaps in radioisotope supply by developing new sources, designing manufacturing facilities that are scalable, and ensuring safety and quality through well-tested release criteria for whole drug products.

Join us as we unite 80+ key stakeholders in CMC, quality assurance, operations, facility managers, and radiopharmacists to bring the targeted radiotherapies to the forefront of cancer treatment.

Capitalizing on the recent successes this space had over the last year, there has never been this amount of demand and excitement for the TRP community. Take advantage of this platform to hear in-depth challenges and solutions in the global TRP manufacturing landscape.

URLs:
Website: https://go.evvnt.com/1729138-0?pid=10018
Brochure: https://go.evvnt.com/1729138-1?pid=10018
Tickets: https://go.evvnt.com/1729138-2?pid=10018
Tickets: https://go.evvnt.com/1729138-3?pid=10018

Prices:
Drug Developer Pricing Conference + 2 Workshops: USD 4297.00,
Drug Developer Pricing Conference + 1 Workshop: USD 3648.00,
Drug Developer Pricing Conference Only: USD 2999.00,
Solution Providers- Conference + 2 Workshops: USD 5297.00,
Solution Providers- Conference + 1 Workshop: USD 4548.00,
Solution Providers- Conference Only: USD 3799.00

Speakers: Anna Kulesza Director - Chemistry, Manufacturing and Controls Clovis Oncology, Dan Saragnese Head of Manufacturing Earli Inc., Diane Abou, Assistant Professor at Washington University in ST. Louis and Lead Chemist at Curium Washington University School of Medicine, Eric Burak Chief Technical Officer Fusion Pharmaceuticals, Geoffrey Johnson Chair of Nuclear Medicine Mayo Clinic, Giuseppe Carlucci Director UCLA Biomedical Cyclotron University of California Los Angeles, Izabela Tworowska Chief Technology Officer Radiomedix Inc, Jarrod Longcor Chief Operating Officer Cellectar Biosciences Inc., Kemp Dolliver Director of Research and Senior Analyst Brookline Capital Markets, Kevin Roland Vice-President Radiopharmaceuticals manufacturing Fusion Pharmaceuticals, Michael Nickels Director - Cyclotron Facility Washington University School of Medicine, Roland Turck Managing Partner TurckBio, Shaemus Gleason Executive Vice President Clarity Pharmaceuticals, Shankar Vallabhajosula Scientific Advisor Convergent Therapeutics, Thomas Birger Eden-Jensen Head of Product Supply Operations Bayer, Vishnu Dwadasi Director - Manufacturing Ashvattha Therapeutics, Ying Cai Director - Supply Chain Ashvattha Therapeutics